<DOC>
	<DOC>NCT01405586</DOC>
	<brief_summary>The purpose of this study is to evaluate the addition of cisplatin to first-line chemotherapy with gemcitabine in elderly patients with non small cell lung cancer in terms of overall survival.</brief_summary>
	<brief_title>MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Cytological or histological diagnosis of non smallcell lung cancer (NSCLC) Stage III B or Stage IV disease Age &gt; or = 70 years ECOG Performance status 0 or 1 Patient at first diagnosis or with recurrence after primary surgery At least one target or nontarget lesion according to RECIST criteria Life expectancy of at least 3 months Neutrophils &gt; 1500/mm3, platelets &gt; 100,000/mm3, hemoglobin &gt; 10g/dl Creatinine &lt; 1.5 x the upper normal limit AST and ALT &lt; 2.5 x the upper normal limits (&lt; 5 x the upper normal limit in the presence of hepatic metastasis) Bilirubin &lt; 1.5 x the upper normal limit Signed informed consent Previous chemotherapy for advanced disease History of malignant neoplasm within the previous 5 years (not including nonmelanoma skin carcinoma and insitu carcinoma of the uterine cervix, provided they are being adequately treated) Symptomatic cerebral or spinal cord metastasis Myocardial infarct within the last 12 months Systemic disease not controlled with treatment (active infection, cardiovascular, hepatic, renal or metabolic) that would not, in the opinion of the investigator, permit the patient to undergo chemotherapy. Known or suspected hypersensitivity to any of the drugs used in the study Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>elderly</keyword>
	<keyword>chemotherapy</keyword>
</DOC>